First Beta Unit of the Aether 1 Bioprinter Ships to the University of Cambridge, Ready to “Absolutely Transform the Entire Bioprinting Market”
About a year ago, a startup called Aether seemed to come right out of the ether, promising a bold new 3D bioprinter with more than 20 swappable extruders. The multipurpose Aether 1 sounded too good to be true, especially coming from a new, unknown company, but it’s already gotten serious interest from a number of universities and research institutions, several of which have signed on to participate in a large-scale research project using Aether 1 beta units.
A few days ago, that project officially began as Aether shipped their first beta unit to the University of Cambridge. Bioengineering professor Dr. Yan Yan Shery Huang, along with her student Elisabeth Gill, will be the first to try out the Aether 1. Dr. Huang specializes in bioengineering, with a particular focus on bioprinting and other novel fabrication techniques – and the Aether 1 certainly meets the criteria for novel fabrication. Aether hopes that the machine will make a valuable contribution to Dr. Huang and Gill’s research, but the pair will also assist in the printer’s further development by testing it and offering feedback.
“Since this is the very first beta unit, it’s a bit ‘raw’ and there are many improvements that need to be made, and problems that remain to be solved,” Aether states. “As our first beta users, they will likely discover new issues, both large and small, that we aren’t aware of yet.”
The Aether 1, in addition to its bioprinting capabilities, offers multiple other fabrication options from food printing to electronics printing to laser engraving. According to Aether, the printer’s major core functions, including options for FDM/FFF 3D printing, syringe extrusion, droplet jetting, and laser engraving, are in place and have been performing well in tests, as are the machine’s four primary automation features: machine vision-based fully automatic air pressure calibration; automatic true mechanical stage leveling; dual automatic multi-function cleaning stations; and automatic offset calibration.
The Aether 1’s automated features are one of its key selling points, in addition to its multitudinous fabrication capabilities. Bioprinting is no simple task, but according to Aether, they’ve made it a lot easier by automating the most complicated and time-consuming parts of the process, ensuring accuracy by replacing “eyeball approximations” with precise sensors and algorithms.
The printer is also remarkably inexpensive at $9,000. Other high-end bioprinters can run as expensive as $250,000 or more, while offering fewer extruders and fabrication methods, and “maybe 1 automation method,” as the company’s CEO tells us. He continues, noting that more comparably priced ($10K-$20K) bioprinters offer even fewer extruders and fabrication methods, with zero automation.
“Aether 1 has up to 24 extruders, 8 fabrication methods, and 4 never-before-seen, totally revolutionary automation features. It crushes the high-end, but it’s priced on the low-end,” Aether CEO Ryan Franks tells 3DPrint.com. “Aether’s shipment to Cambridge marks the beginning of a radical paradigm shift for what researchers can do with a bioprinter, which will soon absolutely transform the entire bioprinting market.”
As the Aether 1 shipped out to Cambridge, the company was in transit as well, moving from their cramped 250-square-foot office to a 2,600-square-foot office in San Francisco’s South of Market (SoMa) district. A larger space has become increasingly necessary as Aether adds to their team; recently they expanded their engineering team and are looking to further increase its size.
Production will be scaling up as well; Aether hopes to ship additional beta units out towards the end of the month, with the goal of sending them to all of the institutions that have signed on for research collaborations as soon as possible. Discuss in the Aether forum at 3DPB.com.
You May Also Like
3D Printing for COVID-19, Part Five: Face Shields and Masks
As a hospitalist mentioned in a previous post on the efforts of 3D printing companies to address the coronavirus outbreak, some 3D-printed parts may be safer and easier to deploy....
3D Printing for COVID-19, Part Three: Open Source Ventilators
Since the initial news flurry about how a network of Italian 3D printing users came to the rescue of a hospital on the front lines of the COVID-19 outbreak in...
3D Printing for COVID-19, Part Four: Corporate Partners
As small 3D printing businesses and individual users jump at a chance to support efforts to manufacture critically needed medical supplies, larger corporations also see opportunities to lend aid. Among...
3D Printing COVID-19: First Do No Harm
We must be mindful that just because we can make a design that this design is not necessarily the right one. While I’m buoyed by the 3D printing industry’s efforts...
View our broad assortment of in house and third party products.